$1.52
71.46% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US01438T1060
Symbol
ALDX
Sector
Industry

Aldeyra Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Aldeyra Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Aldeyra Therapeutics, Inc. Price Target

Target Price $10.29
Price $5.33
Potential
Number of Estimates 7
7 Analysts have issued a price target Aldeyra Therapeutics, Inc. 2026 . The average Aldeyra Therapeutics, Inc. target price is $10.29. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 7 Analysts recommend Aldeyra Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Aldeyra Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Aldeyra Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.94 -0.11
46.88% 88.30%
P/E negative
EV/Sales 2.80

7 Analysts have issued a Aldeyra Therapeutics, Inc. forecast for earnings per share. The average Aldeyra Therapeutics, Inc. EPS is

$-0.11
Unlock
. This is
88.30% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.70 280.85%
Unlock
, the lowest is
$-1.07 13.83%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.94 46.88%
2025
$-0.11 88.30%
Unlock
2026
$-0.57 418.18%
Unlock
2027
$0.30 152.63%
Unlock
2028
$1.24 313.33%
Unlock
2029
$1.00 19.35%
Unlock

P/E ratio

Current -5.67 10.53%
2025
-47.89 744.62%
Unlock
2026
-9.28 80.62%
Unlock
2027
17.55 289.12%
Unlock
2028
4.29 75.56%
Unlock
2029
5.33 24.24%
Unlock

Current Aldeyra Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 03 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 03 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today